Indications |
Oral Schizophrenia Adult: 12.5 mg 1-2 times on day 1 followed by 25 mg 1-2 times on day 2, increased gradually in increments of 25-50 mg up to a daily dose of 300 mg within 14-21 days. Subsequent increments of 50-100 mg may be made 1-2 times wkly. Usual dose: 200-450 mg/day. Max: 900 mg/day. Elderly: Initially, 12.5 mg on day 1 increased subsequently by increments of 25 mg. Renal impairment: Mild-moderate renal impairment: use with caution. Severe impairment: contra-indicated. Hepatic impairment: Use with caution and avoid in symptomatic or progressive liver disease or hepatic failure. Oral Psychoses in Parkinson's disease Adult: Initially, 12.5 mg once daily at night, increased in steps of 12.5 mg up to 2 times each wk, not >50 mg/day at the end of the 2nd wk. Usual dose: 25-37.5 mg daily. Max: 100 mg daily. Renal impairment: Mild-moderate renal impairment: use with caution. Severe impairment: contra-indicated. Hepatic impairment: Use with caution and avoid in symptomatic or progressive liver disease or hepatic failure. |
Contraindications |
History of bone marrow disorders including agranulocytosis, circulatory collapse, alcoholic or toxic psychosis, drug intoxication, uncontrolled epilepsy, severe renal, hepatic or cardiac disease; paralytic ileus. Pregnancy and lactation. |
Warnings / Precautions |
Leucocyte counts should be monitored regularly and for at least 4 wk after treatment discontinuation. Renal, hepatic or cardiac impairment; prostatic enlargement, narrow-angle glaucoma; elderly; immobilised patients |
Adverse Reactions |
Drowsiness, dizziness, headache; nausea, vomiting, constipation; anxiety, confusion, fatigue, transient fever. Rarely, dysphagia, acute pancreatitis, cholestatic jaundice; orthostatic hypotension, tachycardia; seizures; hypersalivation. Potentially Fatal: Rarely, thromboembolism. Reversible neutropenia which may progress to a potentially fatal agranulocytosis. Fatal myocarditis. |
Overdose Reactions |
Altered states of consciousness, including drowsiness, delirium, coma, tachycardia, hypotension, respiratory depression or failure, hypersalivation. Aspiration pneumonia, cardiac arrhythmias, seizures have also been reported. Emesis or gastric lavage, followed by activated charcoal to reduce adsorption. Treatment is symptomatic and supportive with monitoring of cardiac and vital signs. Continue monitoring for several days because of risk of delayed effects. Avoid use of epinephrine and derivatives when treating hypotension and quinidine and procainamide when treating cardiac arrhythmia. Forced diuresis, dialysis, haemoperfusion and exchange transfusion unlikely to be of benefit. |
Drug Interactions |
Reduced plasma concentrations with concomitant use of phenytoin. May enhance the central effects of MAOIs. Potentially Fatal: Concurrent use with bone marrow suppressants e.g. carbamazepine, co-trimoxazole, chloramphenicol, penicillamine, sulfonamides, antineoplastics or pyrazolone analgesics; long-acting depot antipsychotics. See Below for More clozapine Drug Interactions |
Mechanism of Actions |
Clozapine has relatively weak dopamine receptor-blocking activity at D1, D2, D3 and D5 receptors but has high affinity for the D4 receptor. It has also blocking effects on serotonin, α-adrenergic histamine H1 and cholinergic receptors. Absorption: Absorbed well from the GI tract (oral); peak plasma concentrations after 2.5 hr. Distribution: Protein-binding: 95%. Metabolism: Hepatic; N-demethylation and N-oxidation by cytochrome P-450 isoenzyme CYP1A2. Excretion: Via urine and faeces (as metabolites and trace amounts of unchanged drug); 12 hr (elimination half-life) |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store below 25°C. |
ATC Classification |
N05AH02 - clozapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics. |
Storage |
Oral: Store below 25°C. |
Available As |
|
Clozapine
Post Review about Clozapine Click here to cancel reply.
Clozapine Containing Brands
Clozapine is used in following diseases
Drug - Drug Interactions of Clozapine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.